Celltrion’s oncology and autoimmune disease treatments are recording steady growth across major countries in Europe, expanding performance across its overall business portfolio. In particular, newly launched products are gaining traction in the market, increasing the company’s influence in Europe.
According to industry sources on the 16th, in oncology, Celltrion’s treatment for metastatic colorectal cancer and breast cancer, Vegzelma (bevacizumab), is maintaining a stable market share in the European market.
In France, the drug has consecutively won key tenders from major procurement organizations, including Unicancer, the country’s largest pharmaceutical purchasing group for university hospitals, as well as Accome (a Normandy public hospital purchasing group) and GRADeS (a regional public hospital purchasing group).
Vegzelma holds a market share exceeding 50% in the bevacizumab market in France.
Following Vegzelma, Celltrion’s France subsidiary is also supplying the breast cancer treatment Herzuma (trastuzumab) nationwide through Unicancer. The blood cancer treatment Truxima (rituximab) has also won a bid from the Paris public hospital network.
Celltrion’s Germany subsidiary is expanding prescriptions by conducting sales and marketing activities targeting key stakeholders, including major general hospitals, private clinics and pharmacies.
Truxima and Vegzelma ranked No. 1 in prescriptions in the retail market, surpassing original and competing biosimilar products, while Herzuma ranked second.
Despite being launched later than competing products, Vegzelma has secured stable market share across countries in Europe, demonstrating its competitiveness.
According to pharmaceutical market research firm IQVIA, as of the fourth quarter of last year, Vegzelma achieved approximately 30% market share in Europe, maintaining the top position in the bevacizumab market.
Avtozma and Yuflyma also show growth
Celltrion’s newly launched autoimmune disease treatments are also expanding their presence in Europe. Avtozma (tocilizumab) has won regional public tenders in areas such as the Basque Country and Madrid in Spain.
The drug has also been selected as a supplier in a tender organized by INGESA, a procurement body under the Ministry of Health, continuing local sales. In neighboring Portugal, both the autoinjector (AI) and vial formulations of Avtozma have been selected as the top-priority suppliers in national tenders, further expanding its market presence.
Avtozma is also showing strong growth in Germany. In the subcutaneous (SC) formulation of tocilizumab, which accounts for the majority of local market demand, sales volume in the first quarter of this year increased 57% compared to the previous quarter. For the intravenous (IV) formulation, sales volume rose 87% in February compared to the previous month.
Celltrion explained that these results in Germany were driven by differentiated sales points, including additional stability data for the IV formulation of Avtozma, as well as strengthened marketing activities targeting medical professionals.
A Celltrion official said, “Following our existing products, newly launched high-margin products are continuing to deliver tender wins and stable prescription growth across major countries in Europe, contributing to revenue growth based on synergies within our product portfolio,” adding, “We will continue to expand product sales performance by further strengthening differentiated product competitiveness and field-focused sales activities.”
